1,2,5,8-tetrahydroxy anthraquinone has been researched along with Cancer of Lung in 5 studies
1,2,5,8-tetrahydroxy anthraquinone: structure in first source
quinalizarin : A tetrahydroxyanthraquinone having the four hydroxy groups at the 1-, 2-, 5- and 8-positions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "MTT assay was performed to evaluate the inhibitory effect of quninalizarin, icotinib or the combination of both on cell proliferation in several lung adenocarcinoma cell lines." | 3.83 | [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms]. ( Dong, XR; Li, K; Li, QW; Li, ZY; Liu, L; Ma, H; Meng, R; Wu, G; Zhang, S; Zhou, FZ; Zhou, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ilkar Erdagi, S | 1 |
| Ngwabebhoh, FA | 1 |
| Yildiz, U | 1 |
| Meng, LQ | 1 |
| Liu, C | 1 |
| Luo, YH | 1 |
| Piao, XJ | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Wang, JR | 1 |
| Wang, H | 1 |
| Xu, WT | 1 |
| Liu, Y | 1 |
| Wu, YQ | 1 |
| Sun, HN | 1 |
| Han, YH | 1 |
| Jin, MH | 1 |
| Shen, GN | 1 |
| Zang, YQ | 1 |
| Li, J | 1 |
| Fang, NZ | 1 |
| Cui, YD | 1 |
| Jin, CH | 1 |
| Li, Q | 2 |
| Zong, Y | 1 |
| Li, K | 3 |
| Jie, X | 1 |
| Hong, J | 1 |
| Zhou, X | 1 |
| Wu, B | 1 |
| Li, Z | 2 |
| Zhang, S | 3 |
| Wu, G | 3 |
| Meng, R | 3 |
| Zhou, F | 1 |
| Zhou, Y | 2 |
| Liu, L | 2 |
| Li, QW | 1 |
| Zhou, FZ | 1 |
| Li, ZY | 1 |
| Ma, H | 1 |
| Dong, XR | 1 |
5 other studies available for 1,2,5,8-tetrahydroxy anthraquinone and Cancer of Lung
| Article | Year |
|---|---|
Pickering stabilized nanocellulose-alginate: A diosgenin-mediated delivery of quinalizarin as a potent cyto-inhibitor in human lung/breast cancer cell lines.
Topics: A549 Cells; Alginates; Anthraquinones; Breast Neoplasms; Cellulose; Diosgenin; Drug Delivery Systems | 2020 |
Quinalizarin exerts an anti-tumour effect on lung cancer A549 cells by modulating the Akt, MAPK, STAT3 and p53 signalling pathways.
Topics: A549 Cells; Anthraquinones; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle Checkpoints; Cell | 2018 |
Involvement of endothelial CK2 in the radiation induced perivascular resistant niche (PVRN) and the induction of radioresistance for non-small cell lung cancer (NSCLC) cells.
Topics: Anthraquinones; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Casein Kinase II; Cytokines; Endo | 2019 |
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
Topics: Adenocarcinoma of Lung; Anthraquinones; Antineoplastic Agents; Apoptosis; Casein Kinase II; Cell Lin | 2019 |
[The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analysis of Variance; Anthraquinones; Apoptosis; Casein Kina | 2016 |